Menarini Group

United States
Total Offices: 3
800 Total Employees
Year Founded: 2003
Stemline Therapeutics, a Menarini Group company headquartered in New York City, is a commercial-stage biopharmaceutical company focused on developing and commercializing novel oncology therapeutics. Founded by Dr. Ivan Bergstein in 2003, the company aims to improve the lives of cancer patients with first-in-class treatments. Its FDA-approved product ELZONRIS (tagraxofusp), a CD123-directed therapy, treats blastic plasmacytoid dendritic cell neoplasm, and its pipeline includes ELZONRIS, SL-701 and SL-801 for various cancers.

Menarini Group Offices

Hybrid Workspace

Employees engage in a combination of remote and on-site work.

Typical time on-site:
United States
Switzerland
United Kingdom